Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
暂无分享,去创建一个
R. Thieroff-Ekerdt | D. Corzo | M. Boyce | Philip Graham | D. Turnquist | R. Anderson | F. van den Berg | J. Cormier | Daniel Grau
[1] N. Santoro,et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause , 2020, Menopause.
[2] M. Kerr,et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial , 2020, Menopause.
[3] D. Timmerman,et al. Treatment of Menopausal Vasomotor Symptoms with Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. , 2019, The Journal of clinical endocrinology and metabolism.
[4] R. Palmiter,et al. A Neural Circuit Underlying the Generation of Hot Flushes. , 2018, Cell reports.
[5] J. Veldhuis,et al. Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men , 2017, Clinical endocrinology.
[6] J. Veldhuis,et al. Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women , 2017, The Journal of clinical endocrinology and metabolism.
[7] L. Huson,et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[8] J. Veldhuis,et al. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women , 2017, Neuroendocrinology.
[9] C. Allaire,et al. Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. , 2017, Fertility and sterility.
[10] S. Horvath,et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study , 2017, Menopause.
[11] J. Veldhuis,et al. Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women , 2016, The Journal of clinical endocrinology and metabolism.
[12] Richard A. Anderson,et al. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. , 2016, The Journal of clinical endocrinology and metabolism.
[13] S. Ramael,et al. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women. , 2016, The Journal of clinical endocrinology and metabolism.
[14] L. Klotz. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer , 2015, Expert opinion on drug metabolism & toxicology.
[15] C. Rose,et al. The NK3 Receptor Antagonist ESN364 Interrupts Pulsatile LH Secretion and Moderates Levels of Ovarian Hormones Throughout the Menstrual Cycle. , 2015, Endocrinology.
[16] R. Ferriani,et al. Add-back therapy with GnRH analogues for uterine fibroids. , 2015, The Cochrane database of systematic reviews.
[17] J. George,et al. The kisspeptin-GnRH pathway in human reproductive health and disease , 2014, Human reproduction update.
[18] A. A. Romanovsky,et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes , 2013, Frontiers in Neuroendocrinology.
[19] Jacques Young,et al. Kisspeptin Restores Pulsatile LH Secretion in Patients with Neurokinin B Signaling Deficiencies: Physiological, Pathophysiological and Therapeutic Implications , 2012, Neuroendocrinology.
[20] P. Malherbe,et al. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 – 2010) , 2011, Expert opinion on therapeutic patents.
[21] B. Steiniger-Brach,et al. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications. , 2010, Current opinion in drug discovery & development.
[22] S. Bloom,et al. The kisspeptin system of the human hypothalamus: sexual dimorphism and relationship with gonadotropin‐releasing hormone and neurokinin B neurons , 2010, The European journal of neuroscience.
[23] Frank Reimann,et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction , 2009, Nature Genetics.
[24] D. Schoenfeld,et al. Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist. , 1988, The Journal of clinical endocrinology and metabolism.